

Physician Publications and Presentations

Thoracic • Socinski

Presentations

Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, **Socinski MA**, Chiappori A, **Mekhail T**, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH; study investigators; "Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial"; *Lancet Oncol*. Feb. 2016;17(2):234-42. doi: 10.1016/S1470-2045(15)00488-X.

Gadgeel SM, Shaw AT, Govindan R, Gandhi L, **Socinski MA**, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI; "Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer"; *J Clin Oncol*. Dec. 2016; 34(34):4079-4085.

Hirsh V, Ko A, Pilot R, Renschler MF, **Socinski MA**; "Weekly nab-Paclitaxel in Combination with Carboplatin as First-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes"; *Clin Lung Cancer* Sept. 2016; 17(5):367-374. doi: 10.1016/j.clcc.2016.04.002.

Paz-Ares L, **Socinski MA**, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR; "Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer"; *Ann Oncol*. Aug. 2016;27(8):1573-9. doi: 10.1093/annonc/mdw214.

Reck M, **Socinski MA**, Luft A, Szcz-sna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N; "The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial"; *J Thorac Oncol*. June 2016; 11(6):808-18. doi: 10.1016/j.jtho.2016.03.002.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, **Socinski MA**, Chiappori A, **Mekhail T**, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SH; study investigators. *Lancet Oncol*. 2016 Feb;17(2):234-42. doi: 10.1016/S1470-2045(15)00488-X.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, **Socinski MA**, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. *J Clin Oncol*. 2016 Dec;34(34):4079-4085.

Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes. Hirsh V, Ko A, Pilot R, Renschler MF, **Socinski MA**. *Clin Lung Cancer*. 2016 Sep;17(5):367-374. doi: 10.1016/j.clcc.2016.04.002.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Paz-Ares L, **Socinski MA**, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Ann Oncol. 2016 Aug;27(8):1573-9. doi: 10.1093/annonc/mdw214.

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. Reck M, **Socinski MA**, Luft A, Szcz-sna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N. J Thorac Oncol. 2016 Jun;11(6):808-18. doi: 10.1016/j.jtho.2016.03.002.